July 22, 2026

GBS|CIDP Legislative Agenda 2026 | Advocacy Priorities

Support Robust Research Funding

Currently, there is no cure for GBS, CIDP, or MMN. Patients depend on limited treatment options while often living with some level of disability.  Research is critical to improve diagnostics, develop targeted therapies, and ultimately find cures for these rare conditions. Specifically, the GBS|CIDP Foundation International asks Congress to:

  • Robust and sustained funding for the NIH at $51.3 billion
  • Ensure the Congressionally Directed Medical Research Program at the Department of Defense is funded each year meaningfully. This program is especially important for rare and underfunded diseases.
  • Add GBS to the list of conditions able to receive research funding through the Department of Defense Peer Reviewed Medical Research Program

Support the HELP Copays Act

Many patients with rare diseases rely on copay assistance programs to afford their necessary treatments, even when they have insurance. In particular, patients receiving immunoglobulin (IG) therapy often depend on copay assistance programs to maintain consistent access to treatment, care that can be essential in preventing disability for some individuals.

Unfortunately, insurers are increasingly using loopholes to block this assistance from counting towards deductibles and out-of-pocket limits.  Without copay assistance protection, even insured patients may face unmanageable costs.

  • Please consider becoming a cosponsor of the HELP Copays Act (HR 6423 / S 864)
Categories:

Other Articles You May Like

✕